Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
C-type lectin domain family 7 member A (CLEC7A), commonly known as Dectin-1, is a type II transmembrane pattern recognition receptor primarily expressed on myeloid cells, including macrophages, dendritic cells, and neutrophils [1, 12]. It serves as the principal receptor for beta-1,3-linked and beta-1,6-linked glucans, which are essential structural components of fungal cell walls [3, 17]. Upon ligand binding, Dectin-1 initiates a signaling cascade through its cytoplasmic hemITAM motif and Spleen Tyrosine Kinase (Syk), leading to the activation of NF-kappaB and the subsequent production of pro-inflammatory cytokines and reactive oxygen species [7, 15]. This receptor plays a vital role in antifungal immunity and is increasingly targeted in cancer immunotherapy, where beta-glucan agonists are used to prime the innate immune system to enhance the efficacy of monoclonal antibodies [6, 16]. Beyond infection and oncology, Dectin-1 is involved in sterile inflammation, neurodegenerative conditions like Alzheimer's disease, and metabolic disorders, where its modulation can either promote protective immune responses or contribute to pathological inflammation [1, 10, 12]. Therapeutic strategies currently focus on utilizing Dectin-1 agonists as immunomodulators or developing inhibitors to manage chronic inflammatory diseases [7, 8].
Dectin-1 agonists, such as beta-glucans, bind to the extracellular carbohydrate recognition domain, inducing receptor clustering and phosphorylation of the intracellular hemITAM motif. This recruits Spleen Tyrosine Kinase (Syk), which activates downstream signaling pathways including NF-kappaB and MAPK to stimulate the production of pro-inflammatory cytokines (e.g., TNF-alpha, IL-6) and enhance phagocytic activity against pathogens and tumor cells. Conversely, Dectin-1 inhibition or antagonism is explored to mitigate chronic neuroinflammation and sterile inflammatory responses.
6 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on C-type lectin domain family 7 member A (CLEC7A) (Dectin-1).